Odon Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 11.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 9.00 Cr
as on 16-11-2024
- Company Age 3 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 16.00 Cr
as on 16-11-2024
- Revenue %
(FY 2023)
- Profit 242.94%
(FY 2023)
- Ebitda -116.07%
(FY 2023)
- Net Worth 2.44%
(FY 2023)
- Total Assets 16596.29%
(FY 2023)
About Odon Lifesciences
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 11.00 Cr and a paid-up capital of Rs 9.00 Cr.
The company currently has active open charges totaling ₹16.00 Cr.
Ram Jain and Saurabh Jain serve as directors at the Company.
- CIN/LLPIN
U85190DL2021PTC387627
- Company No.
387627
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Oct 2021
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Odon Lifesciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Saurabh Jain  | Director | 04-Oct-2021 | Current |
| Ram Jain | Director | 04-Oct-2021 | Current |
Financial Performance of Odon Lifesciences.
Odon Lifesciences Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 242.94% increase in profit. The company's net worth moved up by a moderate rise of 2.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Odon Lifesciences?
Unlock access to Odon Lifesciences's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
_O.webp)
East African India Overseas Private LimitedActive 40 years 10 monthsRam Jain and Saurabh Jain are mutual person
Odon Prime Pharma Private LimitedActive 7 months 14 daysRam Jain and Saurabh Jain are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 22 Apr 2023 | ₹16.00 Cr | Open |
How Many Employees Work at Odon Lifesciences?
Odon Lifesciences has a workforce of 0 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Odon Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Odon Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
